Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

@article{Fossella1994PhaseIS,
  title={Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.},
  author={Frank V. Fossella and Jin Soo Lee and William J. Murphy and Scott Michael Lippman and M. Clara Calayag and Ai-Chun Pang and Marvin Chasen and Dong M Shin and Bonnie S. Glisson and Steven Benner},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 6},
  pages={1238-44}
}
PURPOSE We conducted a phase II study to determine the response and toxicity of docetaxel (Taxotere; Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA) in chemotherapy-naive patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS We treated 41 chemotherapy-naive patients who had stage IIIb or IV non-small-cell lung cancer with 100… CONTINUE READING